small molecule

WELIREG

BELZUTIFAN

Loss of exclusivityJune 2042latest FDA-listed patent expiry

CompanyMERCK SHARP AND DOHME CORP A SUB OF MERCK AND CO INC

Drug detail

Brand name	WELIREG
Active ingredient	BELZUTIFAN
Strength	40MG
Dosage form	TABLET
Route	ORAL
Modality	Small molecule
FDA approval	August 2021
Marketing status	RX

Listed patents

Patent	Expires	Type
12358870	June 2042	product
RE49948	September 2034	substance, product
9908845	September 2034	substance, product

Regulatory exclusivity

Code	Expires
ODE-364	August 2028
I-968	May 2028
I-931	December 2026
NCE	August 2026

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

Drug detail

Listed patents

Regulatory exclusivity

More from MERCK SHARP AND DOHME CORP A SUB OF MERCK AND CO INC